26. (Amended) A compound denoted (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.

D²

27. (Amended) A compound denoted (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.

D³

28. The hemigalactarate salt of the compound of claim 26.

29. The hemigalactarate salt of the compound of claim 27.

REMARKS

Claims 21-29 are pending. These claims relate to (2R or S)-(4E or Z)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amines. Claim 25 has been amended to correct a typographical error. Claims 22, 26 and 27 have been amended to be independent claims. Claims 28 and 29 are directed to hemigalactarate salts of the compounds of claims 26 and 27. Support for the newly added claims is found in the specification at least on pages 34-37, which outlines the syntheses of these compounds.

Applicants respectfully submit that all of these claims are in condition for allowance for at least the following reasons.

Rejections under 35 U.S.C. § 103 (a)

Claims 21-27 have been rejected under 35 U.S.C. § 103(a) as obvious in view of U.S. Patent 5,861,423 to Caldwell et al. (Caldwell). Applicants respectfully traverse these rejections.

Applicants previously filed a Declaration under 37 C.F.R. § 1.132 of William S. Caldwell, which distinguished the claimed compounds from the compounds disclosed by Caldwell. If the Examiner believes that the following arguments will not be persuasive unless submitted in a further Declaration under 37 C.F.R. § 1.132, the Examiner is encouraged to contact Applicants' undersigned representative to provide Applicants with an opportunity to file such a Declaration before issuing a further Office Action.

The previously submitted Declaration outlined several important differences between compounds with a methylene (-CH$_2$) group or a -CH(CH$_3$) group (as presently claimed) at a